Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
  • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
  • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
  • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/12—Antidiarrhoeals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
  • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/08—Antiepileptics; Anticonvulsants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
  • A61P25/16—Anti-Parkinson drugs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/22—Anxiolytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/24—Antidepressants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
  • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
  • C07D209/04—Indoles; Hydrogenated indoles
  • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
  • C07D209/04—Indoles; Hydrogenated indoles
  • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
  • C07D209/04—Indoles; Hydrogenated indoles
  • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
  • C07D209/12—Radicals substituted by oxygen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D209/56—Ring systems containing three or more rings
  • C07D209/80—[b, c]- or [b, d]-condensed
  • C07D209/82—Carbazoles; Hydrogenated carbazoles
  • C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D209/56—Ring systems containing three or more rings
  • C07D209/80—[b, c]- or [b, d]-condensed
  • C07D209/82—Carbazoles; Hydrogenated carbazoles
  • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
  • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
  • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
  • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
  • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
  • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems

Definitions

• the present invention relates to bicyclic compounds, in particular to benzimidazole derivatives and to pharmaceutical uses thereof.
• R1 is selected from the group consisting of optionally substituted (CrC 6 alkyl, lower alkoxy, lower alkoxy-lower alkyl, cydoalkyloxy-lower alkyl, lower thioalkyl, lower alkylthio-lower alkyl, cycloalkyl, cycloalkyl-lower alkyl, lower alkenyl and lower alkynyl);
• R2 is selected from the group consisting of optionally substituted (lower alkyl, cycloalkyl, cycloalkyl-lower alkyl, aryl, heteroaryl, aryl-lower alkyl, heteroaryl-lower alkyl);
• R3 is selected from the group consisting of halo, cyano, optionally substituted (lower alkyl, lower alkoxy, lower thioalkyl, lower thioalkenyl, aryl, aryl-lower alkyl, heteroaryl, lower alkenyl, lower alkynyl, heteroaryl, aryl-lower alkyl and heteroaryl-lower alkyl and amino);
• R4 is selected from the group consisting of H, halo, cyano, hydroxy, optionally substituted (lower alkyl, lower alkoxy, lower thioalkyl, lower thioalkenyl, aryl, heteroaryl, aryl-lower alkyl, heteroaryl-lower alkyl, alkenyl, alkynyl and amino) and the group having the formula R8-Z- (CH 2 ) n -;
• Z represents a direct bond or is selected from the group consisting of O, NH, CH 2 , CO, SO, SO 2 or S; wherein R8 is selected from the group consisting of optionally substituted (aryl, heteroaryl, carbocyclic aryl, cycloalkyl, heterocycloalkyl);
• n 0, 1 , 2 or 3;
• R5 is selected from the group consisting of H, halo, cyano, hydroxyl, optionally substituted (lower alkyl, lower alkoxy, lower alkoxy-lower alkyl, aryl, heteroaryl, aryl-lower alkyl, heteroaryl-lower alkyl, alkenyl, alkynyl and amino);
• R6 is selected from the group consisting of halo, cyano, optionally substituted (lower alkyl, lower alkoxy, lower thioalkyl, lower alkenyl, lower alkynyl, lower alkoxy-lower alkyl, aryl, heteroaryl, aryl-lower alkyl, heteroaryl-lower alkyl and amino).
• R7 represents one or more substituents independently selected from the group consisting of H, halo, hydroxyl, optionally substituted (lower alkyl, lower alkoxy, amino, cyano, and carbonyl).
• R1-R8 are independently selected from the group consisting of halogen, hydroxy, lower alkyl, mono or di-lower alkylamino, aminocarbonyl, sulfinyl, sulfonyl, sulfanyl, mono or di-lower alkylaminocarbonyl, amino, carboxy, lower alkoxy, C -C-i 2 cycloalkyl, C 3 -C 18 heterocycloalkyl, lower alkylcarbonyl, lower alkoxycarbonyl, nitryl, aryl; all of which, except halogen, are independently optionally substituted by one or more substituents, selected from the group consisting of halogen, hydroxy, lower alkyl, mono or di-lower alkylamino, aminocarbonyl, sulfinyl, sulfonyl, sulfanyl, mono or di-lower alkylaminocarbonyl, amino, carboxy, lower
• lower when referring to organic radicals or compounds means a compound or radical with may be branched or unbranched with up to and including 7 carbon atoms.
• a lower alkyl group may be branched, unbranched or cyclic and contains 1 to 7 carbon atoms, preferably 1 to 4 carbon atoms.
• Lower alkyl represents, for example: methyl, ethyl, propyl, butyl, isopropyl, isobutyl, tertiary butyl or 2,2-dimethylpropyl.
• a lower alkoxy group may be branched or unbranched and contains 1 to 7 carbon atoms, preferably 1 to 6 carbon atoms.
• Lower alkoxy represents, for example: methoxy, ethoxy, propoxy, butoxy, isopropoxy, isobutoxy or tertiary butoxy.
• Lower alkoxy includes cycloalkyloxy and cycloalkyl - lower alkyloxy.
• a lower alkene, alkenyl or alkenoxy group is branched or unbranched and contains 2 to 7 carbon atoms, preferably 1 to 4 carbon atoms and contains at least one carbon-carbon double bond.
• Lower alkene, lower alkenyl or lower alkenyloxy represents for example vinyl, prop-1-enyl, allyl, butenyl, isopropenyl or isobutenyl and the oxy equivalents thereof.
• a lower akyne or alkynyl group is branched or unbranched and contains 2 to 7 carbon atoms, preferably 1 to 4 carbon atoms and contains at least one carbon-carbon triple bond.
• Lower alkyne or lower alkynyl or lower alkenyloxy represents for example ethynyl or propynyl.
• oxygen containing substituents e.g. alkoxy, alkenyloxy, alkynyloxy, carbonyl, etc. encompass their sulphur containing homologues, e.g. thioalkyl, alkyl-thioalkyl, thioalkenyl, alkenyl-thioalkyl, thioalkynyl, thiocarbonyl, sulphone, sulphoxide etc.
• Halo or halogen represents chloro, fluoro, bromo or iodo.
• Aryl represents carbocyclic aryl, heterocyclic aryl or biaryl.
• Carbocyclic aryl is an aromatic cyclic hydrocarbon containing from 6 to 18 ring atoms. It can be monocyclic, bicyclic or tricyclic, for example naphthyl, phenyl, or phenyl mono-, di- or trisubstituted by one, two or three substituents.
• Heterocyclic aryl is an aromatic monocyclic or bicyclic hydrocarbon containing from 5 to 18 ring atoms one or more of which are heteroatoms selected from O, N or S. Preferably there are one or two heteroatoms.
• Heterocyclic aryl represents, for example: pyridyl, indolyl, quinoxalinyl, quinolinyl, isoquinolinyi, benzothienyl, benzofuranyl, benzopyranyl, benzothiopyranyl, furanyl, pyrroly), thiazolyl, oxazolyl, isoxazoly), triazolyl, tetrazoiyl, pyrazolyl, imidazolyl, thienyl, oxadiazolyl, benzimidazolyl. Heterocyclic aryl also includes such substituted radicals.
• Cycloalkyl represents a cyclic hydrocarbon containing from 3 to 12 ring atoms preferably from 3 to 6 ring atoms. Cycloalkyl represents, for example: cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. The cycloalkyl may optionally be substituted.
• Heterocycloalkyl represents a mono-, di- or tricyclic hydrocarbon which may be saturated or unsaturated and which contains one or more, preferably one to three heteroatoms selected from O, N or S. Preferably it contains between three and 18 ring atoms.
• the term heterocycloalkyl is intended also to include bridged heterocycloalkyl groups such as 3- hyroxy-8-aza-bicyclo[3.2.1]oct-8-yl.
• Pharmaceutically acceptable salts include acid addition salts with conventional acids, for example mineral acids, e.g. hydrochloric acid, sulfuric or phosphoric acid, or organic acids, for example aliphatic or aromatic carboxylic or sulfonic acids, e.g.
• pharmaceutically acceptable salts also represent metal or ammonium salts, such as alkali metal or alkaline earth metal salts, e.g. sodium, potassium, magnesium or calcium salts, as well as ammonium salts, which are formed with ammonia or suitable organic amines.
• the agents of the invention which comprise free hydroxyl groups may also exist in the form of pharmaceutically acceptable, physiologically cleavable esters, and as such are included within the scope of the invention.
• Such pharmaceutically acceptable esters are preferably prodrug ester derivatives, such being convertible by solvolysis or cleavage under physiological conditions to the corresponding agents of the invention which comprise free hydroxyl groups.
• Suitable pharmaceutically acceptable prodrug esters are those derived from a carboxylic acid, a carbonic acid monoester or a carbamic acid, advantageously esters derived from an optionally substituted lower alkanoic acid or an arylcarboxylic acid.
• a second aspect of the invention provides a compound of formula (I') or a pharmaceutically acceptable salt, or prodrug ester thereof:
• R' t is selected from the group consisting of optionally substituted (C C 6 alkyl, lower alkoxy- lower alkyl, lower alkynyl, lower thioalkyl-lower alkyl, cycloalkyl-lower alkyl);
• R' 2 is lower alkyl
• R' 3 is selected from the group consisting of halo, cyano, optionally substituted (lower alkyl, lower alkoxy, lower thioalkyl, lower thioalkenyl, lower alkynyl, aryl and aryl-lower alkyl);
• R' 4 is selected from the group consisting of H, halo, cyano, optionally substituted (lower alkyl, aryl, aryl-lower alkyl, heteroaryl, heteroaryl-lower alkyl) and the group having the formula R' e - Z(CH 2 ) n -;
• Z represents a direct bond or is selected from the group consisting of O, NH, CH 2 , CO, SO, SO 2 or S;
• R' 8 is selected from the group consisting of optionally substituted (aryl, pyrazolyl, thiazolyl, cyclobutyl, tetrazolyl, pyridyl, indazolyl, pyrazinyl, furanyl, isoxazolyl, pyrrolidinyl, benzimidazolyl, imidazolyl, oxazolyl);
• n 0, 1, 2 or 3;
• R' 5 is H, halo, or lower alkyl;
• R' 6 is selected from the group consisting of halo, optionally substituted (lower alkyl, lower alkoxy, lower alkenyl, lower alkynyl);
• R' 7 represents one or more substituents independently selected from the group consisting of H, halo, hydroxyl, optionally substituted (lower alkyl, lower alkoxy, amino, cyano, and carbonyl);
• R R's being independently selected from the group consisting of halogen, hydroxy, lower alkyl, mono or di-lower alkylamino, aminocarbonyl, sulfinyl, sulfonyl, sulfanyl, mono or di-lower alkylaminocarbonyl, amino, carboxy, lower alkoxy, C 3 -C 12 cycloalkyl, C 3 -C 18 heterocycloalkyl, lower alkylcarbonyl, lower alkoxycarbonyl, nitryl, aryl; all of which, except halogen, are independently optionally substituted by one or more substituents, selected from the group consisting of halogen, hydroxy, lower alkyl, mono or di-lower alkylamino, aminocarbonyl, sulfinyl, sulfonyl, sulfanyl, mono or di-lower alkylaminocarbonyl, amino, carboxy, lower alk
• R3 or R' 3 is halo, ethyl or substituted methyl.
• R3 or R' 3 may be Br, I or CF 3 . More preferably, R3 or R' 3 is Br. Alternatively preferably, R3 or R' 3 is trifluoromethyl. Alternatively preferably, R3 or R' 3 is ethynyl.
• R7 or R' 7 is preferably located at the 2 and/or 2' position of the phenyl ring.
• Preferred compounds of formula I are:
• a pharmaceutical composition comprising a compound of formula (I) in association with a pharmaceutically acceptable excipient, diluent or carrier.
• a compound of formula (I) for promoting the release of parathyroid hormone is provided.
• PTH parathyroid hormone
• analogues and fragments thereof can have a pronounced anabolic effect on bone formation.
• compounds which promote PTH release such as the compounds of the present invention may be used for preventing or treating conditions of bone which are associated with increased calcium depletion or resorption or in which stimulation of bone formation and calcium fixation in the bone is desirable.
• the invention includes a method for preventing or treating bone conditions which are associated with increased calcium depletion or resorption or in which stimulation of bone formation and calcium fixation in the bone is desirable in which an effective amount of a compound of formula (I) as defined above, or a pharmaceutically- acceptable and -cleavable ester, or acid addition salt thereof is administered to a patient in need of such treatment.
• the invention provides a process for preparation of a compound of formula (I) in free or salt form, comprising: (a) introducing a group R4 into a corresponding compound of formula II, R4 being as defined above:
• X is any suitable group capable of substitution by R4 and wherein R1 , R2, R3, R5, R6 and R7 are as defined above; or
• Q is any suitable group capable of substitution by R3 and wherein R1 , R2, R4, R5, R6 and R7 are as defined above; or
• R2-R7 are as defined above;
• process variant (a) is conveniently an iodide group and the transformation is suitably performed by Suzuki coupling, for example by reacting compound II with aryl or heteroaryl-B(OH) 2 in the presence of a palladium catalyst.
• process variant (b) Y is conveniently a methanesulfonic acid methyl ester group and compound III may be reacted with the desired aryl or heteroaryl R4 group in the presence of a base such as sodium hydride in a suitable solvent such as DMF.
• the compound of formula (III) may be reacted with a Grignard reagent denoted by arylMgBr in a suitable solvent e.g. THF to produce, after subsequent treatment with phosphinic acid and iodine, the corresponding compound of formula (I).
• R3 may for example represent a bromo group which may be introduced by reacting N-bromosuccinimide or Br 2 / acetic acid in a suitable solvent with a compound of formula IV wherein Q denotes H.
• Process variant (d) is an N-alkylation in which R1 is conveniently an alkyl group and may be introduced by reacting a corresponding bromoalkyl with a compound of formula V in the presence of a base such as sodium hydride in suitable solvent, for example DMF.
• a suitable oxidizing agent in process (e) is for example oxalyl chloride in DMSO in a Swern oxidation reaction.
• ring closure is conveniently effected by heating to 100°C with acetic acid.
• the compound obtained may be further transformed into another compound of formula I.
• an aryl ring substituent OH may be transformed to a 2-methoxy- ethoxy group conveniently by reaction with 2-(bromoethyl)-methyl ether in the presence of a base.
• the compounds of formula I in free form may be converted into salt forms in conventional manner and vice-versa.
• the compounds of the invention can be recovered from the reaction mixture and purified in conventional manner.
• Isomers such as enantiomers, may be obtained in conventional manner, e.g. by fractional crystallization or asymmetric synthesis from corresponding asymmetrically substituted, e.g. optically active starting materials.
• a seventh aspect invention includes the use of a compound of formula (I) in the manufacture of a medicament for preventing or treating bone conditions which are associated with increased calcium depletion or resorption or in which stimulation of bone formation and calcium fixation in the bone is desirable.
• Agents of the invention may be prepared by processes described below:
• Example 1 4-Bromo-2-(4-isopropyl-phenyl)-7-methoxy-1-(2-methoxy-ethyl)-1 H- benzoimidazole
• R 2.23min (Waters Symmetry C8, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 O in 2min + 0.05% TFA, flow rate 1.0ml/min)
• the starting materials can be prepared as follows:
• the title compound is prepared starting from 4-iodo-2-(4-isopropyl-phenyl)-7-methoxy-1 H- benzoimidazole and (2-bromoethyl)-methyl ether using the same reaction conditions as described in Example! The title compound is obtained as a colorless oil.
• R t 2.31min (Waters Symmetry C8, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 O in 2min + 0.05% TFA, flow rate 1.Oml/min)
• the starting material 4-iodo-2-(4-isopropyl-phenyl)-7-methoxy-1 H-benzoimidazole is prepared from 4-iodo-3-nitro-anisole using exactly the same methodology as described for in Example 1 a)-d).
• R t 2.36min (Waters Symmetry C8, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 O in 2min + 0.05% TFA, flow rate 1.0ml/min)
• R t 2.31min (Waters Symmetry 08, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 0 in 2min + 0.05% TFA, flow rate 1.0ml/min)
• R t 2.23min (Waters Symmetry 08, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 O in 2min + 0.05% TFA, flow rate 1.0ml/min)
• the title compound is prepared starting from 4-chloro-2-(4-isopropyl-phenyl)-7-methoxy-1 H- benzoimidazole and (2-bromoethyl)-methyl ether using the same reaction conditions as described in Example! The title compound is obtained as a colorless oil.
• R 2.18min (Waters Symmetry 08, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 O in 2min + 0.05% TFA, flow rate 1.0ml/min)
• the starting material 4-chloro-2-(4-isopropyl-phenyl)-7-methoxy-1 H-benzoimidazole is prepared from 4-chloro-3-nitro-anisole using exactly the same methodology as described in Example 1 a)-d).
• the title compound is obtained using 3-hydroxyphenyl-boronic acid instead of phenyl-boronic acid using the same procedure as described for the preparation of Example 12 as a white crystalline solid.
• R t 2.18min (Waters Symmetry 08, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 0 in 2min + 0.05% TFA, flow rate 1.0ml/min)
• Example 15 4-(3,5-Dimethoxy-phenyl)-2-(4-isopropyl-phenyl)-7-methoxy-1-(2-methoxy- ethyl)-1 H-benzoimidazole
• the title compound is obtained using 3,5-dimethoxyphenyl-boronic acid instead of phenyl- boronic acid using the same procedure as described for the preparation of Example 12 as a colorless oil.
• R t 2.20min (Waters Symmetry 08, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 O in 2min + 0.05% TFA, flow rate 1.0ml/min)
• Example 16 4-Methyl-2-(4-isopropyl-phenyl)-7-methoxy-1 -(2-methoxy-ethyl)-1 H- benzoimidazole
• the title compound is prepared starting from 4-methyl-2-(4-isopropyl-phenyl)-7-methoxy-1 H- benzoimidazole and (2-bromoethyl)-methyl ether using the same reaction conditions as described in Example! The title compound is obtained as a colorless oil.
• the starting material 4-methyl-2-(4-isopropyl-phenyl)-7-methoxy-1 H-benzoimidazole is prepared from 4-methyl-3-nitro-anisole using the same method as described in Example 1 a)-d).
• the starting material is prepared as follows:
• Example 19 4-Bromo-2-(4-cyclopropyl-phenyl)-7-methoxy-1 -(2-methoxy-ethyl)-1 H- benzoimidazole
• the title compound and the precursors can be prepared using the same synthesis sequence as described in example 1 from 5-Bromo-3-methoxy-benzene-1 ,2-diamine.
• a mixture of 7.5g (40mmo ⁇ ) 2-chloro-1-methoxy-3-nitro-benzene, 14ml diisopropylethylamine and 35ml 2-methoxyethyl amine is heated (180°C oil bath temperature) in a closed steel reactor for 25 min. Then the reaction mixture is cooled to room temperature and is concentrated in vacuo (3 x coevaporation with toluene) to obtain ca. 20g (which contains 85% of the title compound) of a red oil which is used without further purification in the next step.
• the compound is prepared as described in example 23 by using 4-cyclpropyl-benzoic acid instead of 4-isopropyl-benzoic acid.
• Rt 2.455min (Waters Symmetry 08, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 O in 2min + 0.05% TFA, flow rate !0ml/min)
• R t 2.60min (Waters Symmetry 08, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 O in 2min + 0.05% TFA, flow rate 1.Oml/min)
• o R, 2.38min (Waters Symmetry C8, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 O in 2min + 0.05% TFA, flow rate 1.Oml/min)
• Example 28 4-Bromo-2-(4-isopropyl-phenyl)-7-methoxy-1 -(2-methoxy-ethyl)-5- trifluoromethyl-1 H-benzoimidazole
• the title compound and the precursors can be prepared using the same synthesis sequence as described in example 1 and 23 from 5-trifluoromethyl-3-methoxy-benzene-1 ,2-diamine.
• R t 2.73min (Waters Symmetry C8, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 O in 2min + 0.05% TFA, flow rate !0ml/min)
• the title compound can be prepared using the same synthesis sequence as described in example 28 by using bromo-methyl-cyclopropane instead of 1-bromo-2-methoxy-ethane.
• R t 2.79min (Waters Symmetry 08, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 O in 2min + 0.05% TFA, flow rate !0ml/min)
• 5-Trifluoro-3-methoxy-benzene-1 ,2-diamine can be prepared starting from 1-methoxy-3- nitro-5-trifluoromethyl-benzene using the same reaction sequence as described for the preparation of 3-bromo-6-methoxy-benzene-1 ,2-diamine as described in example 1 (steps c and d).
• the starting material can be prepared as follows:
• the title compound is prepared starting from 5-Bromo-2-(4-isopropyl-phenyl)-7-methoxy-1- (2-methoxy-ethyl)-1 H-benzoimidazole using the same methodology as described for the preparation of example 11.
• R t 2.24min (Waters Symmetry 08, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 O in 2min + 0.05% TFA, flow rate 1.0ml/min)
• Example 33 4-Bromo-2-(4-isopropyl-phenyl)-7-methoxy-1 -(2-methoxy-ethyl)-1 H- benzoimidazole-5-carbonitrile
• R t 2.30min (Waters Symmetry 08, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 0 in 2min + 0.05% TFA, flow rate 1.0ml/min)
• R t 2.38min (Waters Symmetry C8, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 O in 2min + 0.05% TFA, flow rate !0ml/min)
• the starting materials can be prepared as follows:
• Example 38 4-Ethynyl-2-(4-isopropyl-phenyl)-7-methoxy-5-(2-methoxy-benzyl)-1 -(2- methoxy-ethyl)-1 H-benzoimidazole
• Example 39 4-Bromo-5-ethyl-2-(4-isopropyl-phenyl)-7-methoxy-1 -(2-methoxy-ethyl)-1 H- benzoimidazole
• the title compound is prepared using the same methodology as described for the preparation of example 35. (Instead of phenylmagnesiumbromide, ethylmagnesiumbromide is used.)
• R t 2.24min (Waters Symmetry C8, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 O in 2min + 0.05% TFA, flow rate !0ml/min)
• Example 40 4-Bromo-5-cyclobutylmethyl-2-(4-isopropyl-phenyl)-7-methoxy-1-(2-methoxy- ethyl)-1 H-benzoimidazole
• R t 2.43min (Waters Symmetry C8, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 O in 2min + 0.05% TFA, flow rate LOml/min)
• Example 42 4-Bromo-5-(3-chloro-benzyl)-2-(4-isopropyl-phenyl)-7-methoxy-1-(2-methoxy- ethyl)-1 H-benzoimidazole
• the title compound is prepared using the same methodology as described for the preparation of example 35. Instead of phenylmagnesiumbromide, 2-lithio-thiazole (prepared from 2-bromo-thiazole and n-BuLi) is used.
• Example 45 4-Bromo-2-(4-isopropyl-phenyl)-7-methoxy-1 -(2-methoxy-ethyl)-5-pyridin-3- ylmethyl-1 H-benzoimidazole
• Example 46 4-Bromo-2-(4-isopropyl-phenyl)-7-methoxy-1 -(2-methoxy-ethyl)-5-(2- methylsulfanyl-benzyl)-1 H-benzoimidazole
• the starting material can be prepared as follows:
• the title compound is prepared using the same methodology as described for the preparation of example 35 (step c). Instead of phenylmagnesiumbromide, 1-bromo- magnesium-2-methylsulfanyl-benzene (prepared from 1-bromo-2-methylsulfanyl-benzene and magnesium) is used.
• R t 2.12min (Waters Symmetry C8, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 0 in 2min + 0.05% TFA, flow rate 1.0ml/min)
• the starting material can be prepared as follows:
• Example 48 4-Bromo-2-(4-isopropyl-phenyl)-5-(2-methanesulfonyl-benzyl)-7-methoxy-1 -(2- methoxy-ethyl)-1 H-benzoimidazole
• the starting material can be prepared as follows:
• the title compound is prepared starting from [4-iodo-2-(4-isopropyl-phenyI)-7-methoxy-1-(2- methoxy-ethyl)-1 H-benzoimidazol-5-yl]-(2-methoxy-phenyl)-methanol using the same methodology as described for the preparation of example 46 (step a).
• the starting material can be prepared as follows:
• the title compound is prepared from 4-iodo-2-(4-isopropyl ⁇ phenyl)-7-methoxy-1-(2-methoxy- ethyl)-1 H-benzoimidazole- 5-carbaldehyde and 2-methoxyphenyl-magnesium bromide as described in example 35.
• the title compound is prepared from 2-(4-isopropyl-phenyl)-7-methoxy-1-(2-methoxy-ethyl)- 1 H-benzoimidazole-5-carbaldehyde (preparation see example 35) as described in example 59.
• Example 51 4-Bromo-2-(4-isopropyl-phenyl)-7-methoxy-5-(2-methoxy-benzyl)-1 -(2-methoxy- ethyl)-1 H-benzoimidazole
• the starting material can be prepared as follows: [4-Bromo-2-(4-isopropyl-phenyl)-7-methoxy-1-(2-methoxy-ethyl)-1 H-benzoimidazol-5-yl]-(2- methoxy-phenyl)-methanol
• the title compound is prepared from 4-bromo-2-(4-isopropyl-phenyl)-7-methoxy-1-(2- methoxy-ethyl)-1 H-benzoimidazole-5-carbaIdehyde (see example 41 , step c) and 2- methoxyphenyl-magnesium bromide as described in example 35.
• Example 52 4-Bromo-5-(3,4-dimethoxy-benzyl)-2-(4-isopropyl-phenyl)-7-methoxy-1 -(2- methoxy-ethyl)-1 H-benzoimidazole
• the title compound is prepared using the same methodology as described for the preparation of example 35. Instead of phenylmagnesiumbromide, 3,4-dimethoxyphenyl- magnesium-bromide is used.
• the title compound is prepared using the same methodology as described for the preparation of example 35. Instead of phenylmagnesiumbromide, 2-lithium-3-methoxy- pyridine is used.
• the starting material can be prepared as follows:
• Example 55 4-Bromo-2-(4-isopropyl-phenyl)-7-methoxy-5-(3-methoxy-benzyl)-1 -(2-methoxy- ethyl)-1 H-benzoimidazole
• the title compound is prepared from 4-bromo-2-(4-isopropyl-phenyl)-7-methoxy-1-(2- methoxy-ethyl)-1 H-benzoimidazole-5-carbaldehyde and 3-methoxyphenyl-magnesium bromide as described in examples 35 and 5!
• the title compound can be prepared as described in example 56, using 2-methoxyphenyl magnesium bromide instead of 3-methoxy-phenylmagnesium bromide.
• the title compound is prepared from 2-(4-isopropyl-phenyl)-7-methoxy-1-(2-methoxy-ethyl)- 5-(1-phenyl-ethyl)-1 H-benzoimidazole using the methodology described in example 35.
• the starting materials can be prepared as follows:
• the title compound is prepared from 1-[2-(4-isopropyl-phenyl)-7-methoxy-1-(2-methoxy- ethyl)-1 H-benzoimidazol-5-yI]-1-phenyl-ethanol using the methodology described in example 46 (step a).
• the title compound is prepared from 4-bromo-2-(4-isopropyl-phenyl)-7-methoxy-1-(2- methoxy-ethyl)-1 H-benzoimidazole (example 1) using the same methodology as described for the preparation of example 32.
• R 2.42min (Waters Symmetry C8, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 O in 2min + 0.05% TFA, flow rate 1.0ml/min)
• R t 2.16min (Waters Symmetry 08, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 0 in 2min + 0.05% TFA, flow rate !0ml/min)
• Example 62 4-Benzyl-2-(4-isopropyl-phenyl)-7-methoxy-1 -(2-methoxy-ethyl)-1 H- benzoimidazole
• R t 2.23min (Waters Symmetry C8, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 0 in 2min + 0.05% TFA, flow rate !0ml/min)
• R t 2.73min (Waters Symmetry 08, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 0 in 2min + 0.05% TFA, flow rate 1.0ml/min)
• Example 65 4-Bromo-2-(4-isopropyl-phenyl)-7-methoxy-1 -(2-methoxy-ethyl)-5-phenyl-1 H- benzoimidazole
• R 2.42min (Waters Symmetry C8, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 0 in 2min + 0.05% TFA, flow rate 1.0ml/min)
• Example 68 4-Bromo-2-(4-isopropyl-phenyl)-7-methoxy-1-(2-methoxy-ethyl)-5-(3-methoxy- phenyl)-1 H-benzoimidazole
• R t 2.42min (Waters Symmetry 08, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 0 in 2min + 0.05% TFA, flow rate 1.0ml/min)
• R t 2.50min (Waters Symmetry 08, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 0 in 2min + 0.05% TFA, flow rate 1.0ml/min)
• Example 70 4-[4-Bromo-2-(4-isopropyl-phenyl)-7-methoxy-1-(2-methoxy-ethyl)-1H- benzoimidazol-5-yl]-benzoic acid ethyl ester
• R t 2.51min (Waters Symmetry 08, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 O in 2min + 0.05% TFA, flow rate 1.0ml/min)
• R t 2.00min (Waters Symmetry 08, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 O in 2min + 0.05% TFA, flow rate !0ml/min)
• R t 2.38min (Waters Symmetry 08, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 O in 2min + 0.05% TFA, flow rate 1.0ml/min)
• Example 73 1 - ⁇ 5-[4-Bromo-2-(4-isopropyl-phenyl)-7-methoxy-1 -(2-methoxy-ethyl)-1 H- benzoimidazol-5-yl]-2-methoxy-phenyl ⁇ -ethanone
• Example 75 2-(4-lsopropyl-phenyl)-7-methoxy-1 -(2-methoxy-ethyl)-5-(3-methoxy-phenyl)- 1 H-benzoimidazole
• Example 76 4-lodo-2-(4-isopropyl-phenyl)-7-methoxy-1-(2-methoxy-ethyl)-5-pyridin-4-yl-1 H- benzoimidazole
• the compound is prepared using the methodology described in Example 40.
• the product of this reaction 2-(4-lsopropyl-phenyl)-7-methoxy-1 -(2-methoxy-ethyl)-5-pyridin-4-yl-1 H- benzoimidazole, is iodinated as described in example 59 to afford the product.
• R t 2.008min (Waters Symmetry C8, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 O in 2min + 0.05% TFA, flow rate 1.0ml/min)
• R t 2.28min (Waters Symmetry 08, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 O in 2min + 0.05% TFA, flow rate 1.Oml/min)
• the starting materials can be prepared as follows:
• Example 78 4-Bromo-5-imidazol-1-ylmethyl-2-(4-isopropyl-phenyl)-7-methoxy-1-(2-methoxy- ethyl)-1 H-benzoimidazole
• Example 79 4-Bromo-5-(4-bromo-5-methyl-pyrazol-1 -ylmethyl)-2-(4-isopropyl-phenyl)-7- methoxy-1 -(2-methoxy-ethyl)-1 H-benzoimidazole
• R t 2.36min (Waters Symmetry 08, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 O in 2min + 0.05% TFA, flow rate 1.Oml/min)
• Example 81 4-Bromo-5-(3,5-dimethyl-pyrazol-1-ylmethyl)-2-(4-isopropyl-phenyl)-7-methoxy- 1 -(2-methoxy-ethyl)-1 H-benzoimidazole
• Example 82 1-[4-Bromo-1-(2-hydroxy-ethyl)-2-(4-isopropyl-phenyl)-7-methoxy-1 H- benzoimidazol-5-ylmethyl]-1 H-imidazole-2-carboxylic acid ethyl ester 0
• Example 83 4-Bromo-2-(4-isopropyl-phenyl)-7-methoxy-1 -(2-methoxy-ethyl)-5-(2- methoxymethyl-imidazol-1 -ylmethyl)-1 H-benzoimidazole
• Example 84 4-Bromo-2-(4-isopropyl-phenyl)-7-methoxy-1 -(2-methoxy-ethyl)-5-(2- methylsulfanyl-imidazol-1 -ylmethyl)-1 H-benzoimidazole O
• Example 85 1 -[4-Bromo-2-(4-isopropyl-phenyl)-7-methoxy-1 -(2-methoxy-ethyl)-1 H- benzoimidazol-5-ylmethyl]-1 H-benzoimidazol-2-ol
• R t 2.20min (Waters Symmetry 08, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 0 in 2min + 0.05% TFA, flow rate 1.Oml/min)
• Example 86 4-Bromo-2-(4-isopropyl-phenyl)-7-methoxy-1 -(2-methoxy-ethyl)-5-(2- methylsulfanyl-benzoimidazol-1 -ylmethyl)-1 H-benzoimidazole
• Example 87 4-Bromo-2-(4-isopropyl-phenyl)-5-(2-methanesulfinyl-benzoimidazol-1 - ylmethyl)-7-methoxy-1 -(2-methoxy-ethyl)-1 H-benzoimidazole
• R 2.20min (Waters Symmetry 08, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 O in 2min + 0.05% TFA, flow rate !0ml/min)
• Example 88 4-Bromo-2-(4-isopropyl-phenyl)-7-methoxy-5-(2-methoxy-benzoimidazol-1- ylmethyl)-1-(2-methoxy-ethyl)-1 H-benzoimidazole
• R t 2.26min (Waters Symmetry C8, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 O in 2min + 0.05% TFA, flow rate 1. Oml/min)
• R t 2.34min (Waters Symmetry 08, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 0 in 2min + 0.05% TFA, flow rate 1.Oml/min)
• Example 92 2-[4-Bromo-2-(4-isopropyl-phenyl)-7-methoxy-5-(5-methyl-tetrazol-2-ylmethyl)- benzoimidazol-1 -yl]-ethanol
• R 2.21min (Waters Symmetry 08, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 0 in 2min + 0.05% TFA, flow rate 1.Oml/min)
• the compound is prepared as described in example 79 by using 4-cyclopropyl-benzoic acid instead of 4-isopropyl-benzoic acid.
• R t 2.28min (Waters Symmetry C8, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 0 in 2min + 0.05% TFA, flow rate 1.Oml/min)
• the compound is prepared using as described in example 77 by using 1-bromo-2- methylsulfanyl-ethane instead of 1-bromo-2-methoxy-ethane
• Example 96 1 -[4-Bromo-2-(4-isopropyl-phenyl)-7-methoxy-1 -(2-methoxy-ethyl)-1 H- benzoimidazol-5-ylmethyl]-pyrroIidin-2-one
• the title compound is prepared from 1-[2-(4-isopropyl-phenyl)-7-methoxy-1-(2-methoxy- ethyl)-1 H-benzoimidazol-5-ylmethyl]-pyrrolidin-2-one using the same methodology as described in example 35.
• the starting material can be prepared as follows:
• Example 97 4-Bromo-2-(4-isopropyl-phenyl)-7-methoxy-1 -(2-methoxy-ethyl)-5- phenylsulfanyl-1 H-benzoimidazole
• the starting material 2-(4-isopropyl-phenyl)-7-methoxy-1-(2-methoxy-ethyl)-5-phenylsulfanyl- 1 H-benzoimidazole can be prepared as follows:
• the title compound is prepared from 4-bromo ⁇ 2-(4-isopropyl-phenyl)-7-methoxy-1-(2- methoxy-ethyl)-5-phenylsulfanyl-1 H-benzoimidazole using the method described for the preparation of example 47 (oxidation reaction carried out at 40°C for 4h).
• R, 2.45min (Waters Symmetry 08, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 O in 2min + 0.05% TFA, flow rate 1.Oml/min)
• Example 98a 4-Bromo-2-(4-isopropyl-phenyl)-7-methoxy-1 -(2-methoxy-ethyl)-5-phenoxy- 1 H-benzoimidazole
• R t 2.39min (Waters Symmetry 08, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 O in 2min + 0.05% TFA, flow rate !0ml/min)
• R t 2.40min (Waters Symmetry C8, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 0 in 2min + 0.05% TFA, flow rate 1.Oml/min)
• the starting material 2-(4-isopropyl-phenyl)-7-methoxy-1-(2-methoxy-ethyl)-4-trifluoromethyl- 1 H-benzoimidazole-5-carbaldehyde can be prepared as follows:
• Example 100 2-(4-lsopropyl-phenyl)-7-methoxy-5-(2-methoxy-benzyl)-1 -(2-methoxy-ethyl)- 4-trifluoromethyl-1 H-benzoimidazole
• R t 2.40min (Waters Symmetry 08, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 0 in 2min + 0.05% TFA, flow rate !0ml/min)
• Example 101a 2-(4-lsopropyl-phenyl)-7-methoxy-1-(2-methoxy-ethyl)-5-thiazol-2-ylmethyl-4- trifluoromethyl-1 H-benzoimidazole
• Example 102 2-(4-lsopropyl-phenyl)-7-methoxy-1 -(2-methoxy-ethyl)-5-pyrazol-1 -ylmethyl-4- trifluoromethyl-1 H-benzoimidazole
• the title compound is prepared from methanesulfonic acid 2-(4-isopropyl-phenyl)-7-methoxy- 1-(2-methoxy-ethyl)-4-trifluoromethyl-1 H-benzoimidazol-5-ylmethyl ester and pyrrazole as described in examples 35 and 77.
• the starting material methanesulfonic acid 2-(4-isopropyl-phenyl)-7-methoxy-1-(2-methoxy- ethyl)-4-trifluoromethyl-1 H-benzoimidazol-5-ylmethyl ester can be prepared from 2-(4- isopropyl-phenyl)-7-methoxy-1-(2-methoxy-ethyl)-4-trifIuoromethyl-1H-benzoimidazole-5- carbaldehyde (see example 99) using the method described for the preparation of methanesulfonic acid 4-bromo-2-(4-isopropyl-phenyl)-7-methoxy-1-(2-methoxy-ethyl)-1H- benzoimidazol-5-ylmethyl ester (example 77).
• Example 103 4-Bromo-2-(4-isopropyl-phenyl)-7-methoxy-1 -(2-methoxy-ethyl)-5-phenoxy methyl-1 H-benzoimidazole
• R t 2.42min (Waters Symmetry 08, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 O in 2min + 0.05% TFA, flow rate 1.Oml/min)
• the starting materials can be prepared as described in example 77 (steps a to c) :
• Example 104 2- ⁇ 2-[4-Bromo-2-(4-isopropyl-phenyl)-7-methoxy-1-(2-methoxy-ethyl)-1H- benzoimidazol-5-ylmethoxy]-phenyl ⁇ -ethanol
• R t 2.26min (Waters Symmetry 08, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 0 in 2min + 0.05% TFA, flow rate !0ml/min)
• Example 105 2- ⁇ 2-[4-Bromo-2-(4-isopropyl-phenyl)-7-methoxy-1-(2-methoxy-ethyl)-1 H- benzoimidazol-5-ylmethoxy]-phenoxy ⁇ -ethanol
• Example 106 ⁇ 2-[4-Bromo-2-(4-isopropyl-phenyl)-7-methoxy-1-(2-methoxy-ethyl)-1 H- benzoimidazol-5-ylmethoxy]-phenyl ⁇ -methanol
• Example 107 N- ⁇ 2-[4-Bromo-2-(4-isopropyl-phenyl)-7-methoxy-1 -(2-methoxy-ethyl)-1 H- benzoimidazol-5-ylmethoxy]-phenyl ⁇ -acetamide
• Example 110 2-[4-Bromo-2-(4-isopropyl-phenyl)-7-methoxy-1-(2-methoxy-ethyl)-1 H- benzoimidazol-5-ylmethoxy]-phenylamine
• Example 111 1- ⁇ 2-[4-Bromo-2-(4-isopropyl-phenyl)-7-methoxy-1-(2-methoxy-ethyl)-1H- benzoimidazol-5-ylmethoxy]-phenyl ⁇ -ethanone
• Example 114 4-Bromo-2-(4-isopropyl-phenyl)-7-methoxy-1-(2-methoxy-ethyl)-5-(pyridin-2- yloxymethyl)-1 H-benzoimidazole
• Example 115 4-Bromo-2-(4-isopropyl-phenyl)-7-methoxy-1-(2-methoxy-ethyl)-5-(2-methoxy- phenoxymethyl)-1 H-benzoimidazole
• Example 116 ⁇ 3-[4-Bromo-2-(4-isopropyl-phenyl)-7-methoxy-1-(2-methoxy-ethyl)-1 H-be nzoimidazol-5-ylmethoxy]-2-methyl-phenyl ⁇ -methanol
• Example 120 2- ⁇ 2-[4-Bromo-2-(4-isopropyl-phenyl)-7-methoxy-1 ⁇ (2-methoxy-ethyl)-1 H- benzoimidazol-5-ylmethoxy]-phenyl ⁇ -acetamide
• Example 121 2- ⁇ 2-[2-(4-lsopropyl-phenyl)-7-methoxy-1-(2-methoxy-ethyl)-4-trifluoromethyl- 1 H-benzoimidazol-5-ylmethoxy]-phenoxy ⁇ -ethanol
• Example 125 [4-Bromo-2-(4-isopropyl-phenyl)-7-methoxy-1 -(2-methoxy-ethyl)-1 H-benzo imidazol-5-ylmethyl]-[2-(2-methanesulfonyl-ethyl)-phenyl]-amine
• Example 126 2-(2- ⁇ [4-Bromo-2-(4-isopropyl-phenyl)-7-methoxy-1 -(2-methoxy-ethyl)-1 H- benzoimidazol-5-ylmethyl]-amino ⁇ -phenyl)-acetamide
• Example 127 2- ⁇ [4-Bromo-2-(4-isopropyl-phenyl)-7-methoxy-1 -(2-methoxy-ethyl)-1 H-be nzoimidazol-5-ylmethyl]-amino ⁇ -benzenesulfonic acid
• Example 128 [4-Bromo-2-(4-isopropyl-phenyl)-7-methoxy-1 -(2-methoxy-ethyl)-1 H-benzo imidazol-5-ylmethyl]-(2-fluoro-phenyl)-amine
• Example 130 2- ⁇ [4-Bromo-2-(4-isopropyl-phenyl)-7-methoxy-1-(2-methoxy-ethyl)-1 H- benzoimidazol-5-ylmethyl]-amino ⁇ -benzoic acid methyl ester
• Example 132 [4-Bromo-2-(4-isopropyl-phenyl)-7-methoxy-1 -(2-methoxy-ethyl)-1 H-benzo imidazo ⁇ -5-y ⁇ methyl]-methy]-pheny ⁇ -am ⁇ ne
• Example 133 [4-Bromo-2-(4-isopropyl-phenyl)-7-methoxy-1 -(2-methoxy-ethyl)-1 H-benzo imidazol-5-ylmethyl]-(3-methanesulfonyl-phenyl)-amine
• Example 134 2-(2- ⁇ [2-(4-lsopropyl-phenyl)-7-methoxy-1 -(2-methoxy-ethyl)-4-trifluoromethyl- 1 H-benzoimidazol-5-ylmethyl]-amino ⁇ -phenyl)-acetamide
• Example 136 [2-(4-lsopropyl-phenyl)-7-methoxy-1 -(2-methoxy-ethyl)-4-trifiuoromethyl-1 H- benzoimidazol-5-ylmethyl]-[2-(2-methanesulfonyl-ethyl)-phenyl]-amine
• R 2.32min (Waters Symmetry 08, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 O in 2min + 0.05% TFA, flow rate 1.Oml/min)
• Example 137 1-[4-Bromo-2-(4-isopropyl-phenyl)-7-methoxy-1-(2-methoxy-ethyl)-1 H- benzoimidazol-5-ylmethyl]-1 H-imidazole-2-carboxylic acid methyl ester
• Example 138 1-[4-Bromo-2-(4-isopropyl-phenyi)-7-methoxy-1-(2-methoxy-ethyl)-1H- benzoimidazol-5-ylmethyl]-1 H-imidazole-2-carboxylic acid dimethylamide
• R t 2.12min (Waters Symmetry 08, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 O in 2min + 0.05% TFA, flow rate 1.Oml/min)
• Example 140 1-[4-Bromo-2-(4-isopropyl-phenyl)-7-methoxy-1-(2-methoxy-ethyl)-1 H- benzoimidazoi-5-ylmethyl]-1H-indole-2,3-dione
• Example 141 4-Bromo-2-(4 ⁇ isopropyl-phenyl)-7-methoxy-1-(2-methoxy-ethyl)-5-oxazol-2- ylmethyl-1 H-benzoimidazole
• Example 142 1-[4-Bromo-2-(4-isopropyl-phenyl)-7-methoxy-1-(2-methoxy-ethyl)-1 H- benzoimidazol-5-ylmethyl]-1H-imidazole-2-carbonitrile
• R t 2.24min (Waters Symmetry 08, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 O in 2min + 0.05% TFA, flow rate 1. Oml/min)
• Example 143 1-[4-Bromo-2-(4-isopropyl-phenyl)-7-methoxy-1-(2-methoxy-ethyl)-1 H- benzoimidazol-5-ylmethyl]-1 H-imidazole-2-carboxylic acid methylamide o
• Rt 2.50min (Waters Symmetry 08, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 O in 2min + 0.05% TFA, flow rate 1.Oml/min)
• R t 2.35min (Waters Symmetry 08, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 0 in 2min + 0.05% TFA, flow rate 1.Oml/min)
• Example 146 [2-(4-lsopropyl-phenyl)-7-methoxy-1 -(2-methoxy-ethyl)-4-trifluoromethyl-1 H- benzoimidazol-5-ylmethyl]-pyridin-2-yl-amine
• R t 2.48min (Waters Symmetry 08, 2.1x50mm, detection 210-250nM, 10% to 95% CH 3 CN in H 2 O in 2min + 0.05% TFA, flow rate 1. Oml/min)

Priority Applications (10)

Applications Claiming Priority (2)

Publications (2)

Family

ID=31726170

Family Applications (1)

Country Status (22)

Cited By (8)

Families Citing this family (6)

Citations (1)

Family Cites Families (11)

• 2004
  • 2004-01-14 GB GBGB0400781.1A patent/GB0400781D0/en not_active Ceased
• 2005
  • 2005-01-12 PE PE2005000058A patent/PE20050762A1/es not_active Application Discontinuation
  • 2005-01-12 AR ARP050100099A patent/AR049861A1/es not_active Application Discontinuation
  • 2005-01-13 KR KR1020067014148A patent/KR100796398B1/ko not_active IP Right Cessation
  • 2005-01-13 CN CN2011100629607A patent/CN102199144A/zh active Pending
  • 2005-01-13 NZ NZ548319A patent/NZ548319A/en unknown
  • 2005-01-13 CA CA002552403A patent/CA2552403A1/en not_active Abandoned
  • 2005-01-13 AU AU2005205141A patent/AU2005205141B2/en not_active Ceased
  • 2005-01-13 TW TW094101020A patent/TW200539877A/zh unknown
  • 2005-01-13 JP JP2006548267A patent/JP4531062B2/ja not_active Expired - Fee Related
  • 2005-01-13 WO PCT/EP2005/000291 patent/WO2005068433A1/en active Application Filing
  • 2005-01-13 SG SG200900257-7A patent/SG149831A1/en unknown
  • 2005-01-13 RU RU2006129348/04A patent/RU2361863C2/ru not_active IP Right Cessation
  • 2005-01-13 CN CNA2005800081741A patent/CN1930133A/zh active Pending
  • 2005-01-13 EP EP05700898A patent/EP1709006A1/en not_active Withdrawn
  • 2005-01-13 BR BRPI0506889-4A patent/BRPI0506889A/pt not_active IP Right Cessation
  • 2005-01-13 US US10/585,480 patent/US8030497B2/en not_active Expired - Fee Related
• 2006
  • 2006-06-29 IL IL176630A patent/IL176630A0/en unknown
  • 2006-07-10 MA MA29180A patent/MA28291A1/fr unknown
  • 2006-07-11 EC EC2006006693A patent/ECSP066693A/es unknown
  • 2006-07-13 TN TNP2006000220A patent/TNSN06220A1/en unknown
  • 2006-07-14 CO CO06068712A patent/CO5700773A2/es not_active Application Discontinuation
  • 2006-08-14 NO NO20063662A patent/NO20063662L/no not_active Application Discontinuation

Patent Citations (1)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events